For which systemic manifestations of Sjögren syndrome should treatment with rituximab be considered?

Updated: Mar 05, 2021
  • Author: Sriya K Ranatunga, MD, MPH; Chief Editor: Herbert S Diamond, MD  more...
  • Print

Rituximab may be considered as a therapeutic option for adults with primary Sjögren syndrome and any or all of the following systemic manifestations:

  • Cryoglobulinemia associated with vasculitis
  • Vasculitis
  • Severe parotid swelling
  •  Inflammatory arthritis
  • Pulmonary disease
  • Peripheral neuropathy, especially mononeuritis

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!